WC
NVAX icon

Wexford Capital’s Novavax NVAX Stock Holding History

Wexford Capital’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-9,593
Closed -$990K – 129
2016
Q1 		$990K Buy
+9,593
New +$1.03M 0.19% 76
2013
Q4 		– Sell
-15,267
Closed -$962K – 253
2013
Q3 		$962K Buy
+15,267
New +$860K 0.08% 117

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wexford Capital's NVAX Position: Q2 2016 in Review

Wexford Capital sold out of Novavax (NVAX) in Q2 2016, closing a stake of 9,593 shares — an estimated $990K sold.

Wexford Capital first reported a position in NVAX in Q3 2013 and held it in 2 quarters. The position peaked at $990K in Q1 2016. 186 funds tracked by Wall St. Rank hold NVAX as of Q2 2016.

  • Wexford Capital reported no remaining Novavax position as of Q2 2016 after selling out during the quarter.
  • Wexford Capital sold 9,593 Novavax shares in Q2 2016, an estimated $990K.
  • Wexford Capital first reported a position in Novavax in Q3 2013 and held it in 2 quarters.
  • Wexford Capital's Novavax position peaked at $990K in Q1 2016.
  • 186 funds tracked by Wall St. Rank held Novavax as of Q2 2016.

Based on Wexford Capital's 13F filing for Q2 2016, filed 12 Aug 2016.